Hautarztpraxis Dr. med. Matthias Hoffmann

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)5 trials
• Psoriasis5 trials
• Hidradenitis suppurativa1 trial
• Psoriatic arthritis1 trial
• Vitiligo1 trial

Phase

• Phase 36 trials
• Phase 24 trials
• Phase 2/31 trial

Status

• Completed7 trials
• Active, not recruiting2 trials
• Recruiting1 trial
• Suspended1 trial

Lead sponsor

• Sanofi5 trials
• AbbVie1 trial
• Arctic Bioscience1 trial
• Arctic Bioscience AS1 trial
• Incyte Corporation1 trial
• and 2 more

Running trials

• Recruiting

  Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

  NCT06855498· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

  NCT06241118· Phase 3· Sanofi· Source

• Active, not recruiting

  Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

  NCT05492578· Phase 2/3· Sanofi· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Hidradenitis suppurativa1 recruiting
• Vitiligo1 recruiting

Closed trials

• Active, not recruiting

  A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06407934· Phase 3· Sanofi· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

  NCT06224348· Phase 3· Sanofi· Source

• Completed

  A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis

  NCT06073119· Phase 2· Sanofi· Source

• Completed

  Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).

  NCT06125808· Phase 2· Arctic Bioscience· Source

• Completed

  An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study)

  2022-501850-12-00· Phase 2· Arctic Bioscience AS· Source

• Completed

  A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

  NCT03818035· Phase 3· Janssen-Cilag International NV· Source

• Completed

  A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

  NCT03607422· Phase 3· AbbVie· Source